So Much for New Ideas

The Wall Street Journal's Health Blog reports that Pfizer named Martin Mackay as the new chief of their struggling R&D program. Jacob Goldstein adds that Mackay, who has been at Pfizer for over ten years, is an odd choice since Pfizer had been looking to bring in fresh blood. Pfizer also announced the launch of a dedicated biotech unit in San Franciso that will be run by Corey Goodman.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

In a survey, about half of Canadian government scientists say they still feel as though they cannot speak freely, ScienceInsider reports.

The Atlantic reports that biohacker Josiah Zayner regrets injecting himself with the CRISPR gene-editing tool on stage.

Clinicians in China are moving ahead with a number of CRISPR trials, NPR reports, as the US embarks on its first.

In Nature this week: genomic approaches applied to study Neolithic and Bronze Age Europeans, and more.